Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,035 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
Nakagawa T, Tanino T, Onishi M, Tofukuji S, Kanazawa T, Ishioka Y, Itoh T, Kugimiya A, Katayama K, Yamamoto T, Nagira M, Ishii KJ. Nakagawa T, et al. Among authors: kanazawa t. Front Immunol. 2021 Dec 23;12:803090. doi: 10.3389/fimmu.2021.803090. eCollection 2021. Front Immunol. 2021. PMID: 35003132 Free PMC article.
Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).
Kusakabe K, Ide N, Daigo Y, Tachibana Y, Itoh T, Yamamoto T, Hashizume H, Hato Y, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Yasuo K, Maeda M, Higaki M, Ueda K, Yoshizawa H, Baba Y, Shiota T, Murai H, Nakamura Y. Kusakabe K, et al. Among authors: kanazawa t. J Med Chem. 2013 Jun 13;56(11):4343-56. doi: 10.1021/jm4000215. Epub 2013 May 24. J Med Chem. 2013. PMID: 23634759
Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation.
Kusakabe K, Ide N, Daigo Y, Itoh T, Higashino K, Okano Y, Tadano G, Tachibana Y, Sato Y, Inoue M, Wada T, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Tagashira S, Kido Y, Sakamoto S, Yasuo K, Maeda M, Yamamoto T, Higaki M, Endoh T, Ueda K, Shiota T, Murai H, Nakamura Y. Kusakabe K, et al. Among authors: kanazawa t. ACS Med Chem Lett. 2012 Jun 6;3(7):560-4. doi: 10.1021/ml3000879. eCollection 2012 Jul 12. ACS Med Chem Lett. 2012. PMID: 24900510 Free PMC article.
Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K, Ide N, Daigo Y, Itoh T, Yamamoto T, Hashizume H, Nozu K, Yoshida H, Tadano G, Tagashira S, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Ando S, Maeda M, Higaki M, Baba Y, Nakamura Y. Kusakabe K, et al. Among authors: kanazawa t. J Med Chem. 2015 Feb 26;58(4):1760-75. doi: 10.1021/jm501599u. Epub 2015 Feb 10. J Med Chem. 2015. PMID: 25625617
A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity.
Kusakabe K, Ide N, Daigo Y, Itoh T, Yamamoto T, Kojima E, Mitsuoka Y, Tadano G, Tagashira S, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Ando S, Maeda M, Higaki M, Yoshizawa H, Murai H, Nakamura Y. Kusakabe K, et al. Among authors: kanazawa t. Bioorg Med Chem. 2015 May 1;23(9):2247-60. doi: 10.1016/j.bmc.2015.02.042. Epub 2015 Mar 4. Bioorg Med Chem. 2015. PMID: 25801152
Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma.
Nishida K, Kawashima A, Kanazawa T, Kidani Y, Yoshida T, Hirata M, Yamamoto K, Yamamoto Y, Sawada M, Kato R, Kato T, Hatano K, Ujike T, Fujita K, Uemura M, Morimoto-Okazawa A, Iwahori K, Yamasaki M, Ohkura N, Sakaguchi S, Nonomura N, Doki Y, Wada H. Nishida K, et al. Among authors: kanazawa t. Int Immunol. 2020 May 8;32(5):347-357. doi: 10.1093/intimm/dxaa004. Int Immunol. 2020. PMID: 31950169
Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients.
Jingushi K, Kawashima A, Saito T, Kanazawa T, Motooka D, Kimura T, Mita M, Yamamoto A, Uemura T, Yamamichi G, Okada K, Tomiyama E, Koh Y, Matsushita M, Kato T, Hatano K, Uemura M, Tsujikawa K, Wada H, Nonomura N. Jingushi K, et al. Among authors: kanazawa t. Cancer Immunol Immunother. 2022 Dec;71(12):2999-3011. doi: 10.1007/s00262-022-03213-5. Epub 2022 May 22. Cancer Immunol Immunother. 2022. PMID: 35598195 Free PMC article.
NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC.
Takeoka T, Nagase H, Kurose K, Ohue Y, Yamasaki M, Takiguchi S, Sato E, Isobe M, Kanazawa T, Matsumoto M, Iwahori K, Kawashima A, Morimoto-Okazawa A, Nishikawa H, Oka M, Pan L, Venhaus R, Nakayama E, Mori M, Doki Y, Wada H. Takeoka T, et al. Among authors: kanazawa t. J Immunother. 2017 May;40(4):140-147. doi: 10.1097/CJI.0000000000000162. J Immunother. 2017. PMID: 28338507
Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point molecules.
Kawashima A, Kanazawa T, Goto K, Matsumoto M, Morimoto-Okazawa A, Iwahori K, Ujike T, Nagahara A, Fujita K, Uemura M, Nonomura N, Wada H. Kawashima A, et al. Among authors: kanazawa t. Cancer Immunol Immunother. 2018 Jan;67(1):113-125. doi: 10.1007/s00262-017-2060-5. Epub 2017 Oct 3. Cancer Immunol Immunother. 2018. PMID: 28975380 Free PMC article.
1,035 results